{"prompt": "['SF36', 'Short Form Health Survey', 'SOF', 'Sofosbuvir', 'SOP', 'Standard operating procedure', 'SUSAR', 'Suspected Unexpected Serious Adverse Reaction', 'SVR', 'Sustained Virologic Response', 'SVR4', 'Sustained viral response 4 weeks after discontinuation of study treatment', 'SVR12', 'Sustained viral response 12 weeks after discontinuation of study treatment', 'SVR24', 'Sustained viral response 24 weeks after discontinuation of study treatment', 'ULN', 'upper limit of the normal range', 'US', 'United States', 'VEL', 'Velpatasvir', 'WBC', 'white blood cell count', 'WOCPB', 'women of childbearing potential', 'CRI 15-05 Protocol 13SEP2017', 'Page 12']['3 INTRODUCTION', '3.1 Background and Rationale', 'An estimated 3.2 million people in the United States are currently infected with hepatitis C virus (HCV).', 'Since 1990, when the US introduced screening of the blood supply for HCV, injection drug use has been', 'the primary mode of HCV transmission in the United States. It is widely recognized that addressing the', 'HCV epidemic among people who inject drugs (PWID) depends on increasing access to: 1) clean injection', 'equipment; 2) opioid substitution therapy (OST); 3) curative HCV treatment; and 4) assistance with', 'comorbid psychiatric conditions and social issues (Robaeys, C et al, 2013).', 'Nevertheless, access to HCV treatment among current and former injection drug users is thought to be', 'limited by several factors including: 1) insufficient number of infectious disease and gastroenterology', 'providers and 2) provider and third-party payor concerns about adherence to medication and the risk of', 'reinfection (Aspinall, EJ et al, 2013). Strategies to increase access among current and former injection', 'drug users to direct acting antiviral drugs are urgently needed. The purpose of the current study is to', 'assess the impact of co-treating chronic hepatitis C infection and opioid dependence within the context', 'of an outpatient addiction clinic staffed by psychiatrists.', 'The partial -agonist, buprenorphine, is effective treatment for opioid dependence. Buprenorphine is', \"typically co-formulated with naloxone and prescribed as buprenorphine/naloxone in a physician's office\", 'by providers who have undergone specialized training and licensure as proscribed by the Drug Abuse', 'Treatment Act of 2000. Currently, there are more than 20,000 licensed buprenorphine/naloxone', 'providers in the United States (Anson, 2013). Importantly, buprenorphine/naloxone patients are usually', 'required to see their buprenorphine/naloxone providers for a new buprenorphine/naloxone prescription', 'at least monthly, if not more frequently, and the adherence to these visits is extremely high. Moreover,', 'buprenorphine/naloxone therapy is often prescribed through multidisciplinary clinics which are highly', 'effective at retaining patients in care because comorbid psychiatric conditions and social problems are', 'also addressed.', 'The beneficial impact of co-treating opioid dependence and an infectious illness has been demonstrated', 'in the case of HIV infection. Altice and colleagues conducted an observational study of HIV-infected', 'opioid-dependent patients who were offered OST with buprenorphine/naloxone at 10 different HIV', 'clinics. Subjects initiating buprenorphine/naloxone were more likely to initiate or remain on', 'antiretroviral therapy (Altice, 2011).', 'The Extension for Community Healthcare Outcomes (ECHO) program has demonstrated that with proper', 'training and mentorship, primary care providers with no prior experience in managing HCV are able to', 'treat the disease effectively. The ECHO project employed video conferencing technology to provide', 'specialist run didactic sessions and consultation to primary care physicians in rural areas and prisons of', 'New Mexico. Between 2004 and 2008, 146 treatment-na\u00efve subjects were treated at the HCV clinic at', 'UNM, and 261 treatment na\u00efve subjects were treated at ECHO sites. Sustained virologic response rates', 'were similar at the academic medical center clinic and ECHO sites (57.5% at UNM HCV clinic versus', '58.2% at ECHO sites, P = .89). At the UNM HCV clinic, 13.7% of patients had serious adverse events, as', 'did 6.9% of those treated at ECHO sites (Arora et al, 2011).', 'Since the publication of the ECHO study, the treatment of HCV has become considerably less', 'complicated due to the widespread availability of safe, highly effective single tablet regimens, such as', 'Epclusa. We believe that treatment of HCV is now well within the grasp of physicians and other', 'healthcare providers without training in internal or family medicine. We propose a single arm pilot study', 'CRI 15-05 Protocol 13SEP2017', 'Page 13']['of HCV treatment with Epclusa at an outpatient addiction clinic in Somerville, Massachusetts staffed by', 'psychiatrists.', 'We hypothesize that:', 'With proper training and mentorship, psychiatrists who are also licensed', 'buprenorphine/naloxone providers will be able to effectively assess liver health and treat', 'chronic hepatitis C infection with Epclusa', 'Patients with chronic hepatitis C infection on buprenorphine/naloxone maintenance therapy', 'who are treated for HCV by a psychiatrist during regularly scheduled visits to an addiction clinic', 'will have high rates of', 'adherence to HCV treatment', 'SVR 12', 'Given that subjects will receive standard of care evaluation and treatment for their chronic hepatitis C', 'infection, we believe that study participation poses minimal risk. Indeed, we believe that subjects will', 'benefit from improved access to this important treatment which will be provided at a convenient', 'location by a known physician under the guidance of an infectious disease physician with extensive', 'experience treating HCV infection.', '3.2 Epclusa', 'Epclusa is a two-drug fixed-dose combination product that contains 100 mg of velpatasvir and 400 mg of', 'sofosbuvir in a single tablet. The recommended dosage of Epclusa is one tablet taken orally once daily', 'with or without food for 12 weeks. Velpatasvir is a pangenotypic HCV NS5A inhibitor and sofosbuvir is a', 'pangenotypic nucleotide inhibitor of HCV NS5B RNA-dependent RNA polymerase.', 'Epclusa was approved by the FDA in 2016 for the treatment of adult patients with chronic hepatitis C', 'infection genotypes 1, 2, 3, 4, 5, and 6. It is recommended as first line therapy for treatment na\u00efve and', 'pegylated-ribavirin-experienced adults with chronic hepatitis C infection genotypes 1-6 (AASLD and IDSA', 'HCV Guidelines, October, 2016). Safety and tolerability data for Epclusa is based on data from three', 'Phase 3 clinical trials (ASTRAL-1, ASTRAL-2, and ASTRAL-3) which enrolled a total of 1035 subjects who', 'either did not have cirrhosis or who had compensated cirrhosis (Epclusa Package Insert).', 'Overall, 0.2% of subjects in the three studies discontinued Epclusa due to adverse events.', 'The most common adverse reactions (>10%) during 12 weeks of treatment with Epclusa were headache', 'and fatigue.', 'ASTRAL-1 was a randomized placebo-controlled trial which enrolled 740 subjects with genotypes 1, 2,', '4,', '5, and 6 chronic HCV. Nineteen percent of these subjects had compensated cirrhosis and 32% were', 'treatment experienced. The table below lists adverse reactions (adverse events assessed as causally', 'related by the Investigator, all grades) observed in >5% of subjects in ASTRAL-1. The majority of adverse', 'reactions were of severity grade 1. Importantly, each of these reactions occurred at a similar frequency', 'or more frequently in the control arm, with the exception of asthenia which occurred in 5% subjects on', 'Epclusa and 3% of subjects on placebo.', 'CRI 15-05 Protocol 13SEP2017', 'Page 14']\n\n###\n\n", "completion": "END"}